A look at Johnson & Johnson 1st-quarter sales by division and selected products, categories

A look at health care giant Johnson & Johnson's first-quarter revenue by division and for selected products and categories:

CONSUMER HEALTH PRODUCTS 1Q 2013  1Q 2012   Change 

U.S. Total $1.35 B  $1.32 B   up 2.4 percent 

International Total $2.33 B  $2.28 B   up 2.1 percent 

Worldwide Total $3.68 B  $3.6 B    up 2.2 percent 

Nonprescription drugs/nutritionals-U.S. $436 M   $381 M    up 14.4 percent 

PRESCRIPTION DRUGS 1Q 2013 1Q 2012 Change 

U.S. Total $3.47 B $3.03 B up 14.7 percent 

International Total $3.3 B  $3.11 B up 6.1 percent 

Worldwide Total $6.77 B $6.13 B up 10.4 percent 

Remicade (immune disorders) $1.6 B  $1.52 B up 5.2 percent 

Stelara (psoriasis) $346 M  $221 M  up 57 percent 

Prezista (HIV) $367 M  $324 M  up 13.3 percent   

Concerta (attention deficit disorder) $256 M  $308 M  down 16.9 percent 

Risperdal Consta (schizophrenia) $335 M  $361 M  down 7.2 percent 

Invega Sustenna (schizophrenia) $284 M  $161 M  up 76.4 percent 

Zytiga (prostate cancer) $344 M  $200 M  up 72 percent 

Velcade (multiple myeloma) $353 M  $353 M  flat  

Procrit (anemia from cancer/dialysis) $378 M  $376 M  up 0.5 percent

Xarelto (clot prevention) $158 M  $27 M   up 485 percent

MEDICAL DEVICES & DIAGNOSTICS 1Q 2013  1Q 2012  Change 

U.S. Total $3.21 B  $2.88 B  up 11.4 percent 

International Total $3.86 B  $3.53 B  up 9.1 percent 

Worldwide Total $7.06 B  $6.41 B  up 10.2 percent 

Diabetes Care-global $600 M   $670 M   down 10.4 percent 

Orthopedic Products-global $2.39 B  $1.49 B  up 59.7 percent 

TOTAL SALES 1Q 2013  1Q 2010  Change 

U.S. $8.03 B  $7.22 B  up 11.2 percent 

International $9.48 B  $8.92 B  up 6.3 percent 

Worldwide Total $17.51 B $16.14 B up 8.5 percent 

Note: Orthopedic sales jumped mainly due to the huge Synthes acquisition.

____

Source: Johnson & Johnson